Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.
Recurrent or Metastatic Breast Cancer
DRUG: DHP107|DRUG: IV Paclitaxel
Objective Response Rate(ORR), ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria, Every 8 weeks upto 18 months from randomization date
Progression free survival(PFS), PFS is defined as the time from date of randomization until the date of first documented progression or death., Up to 18 months from randomization date|Overall survival(OS), OS is defined as the time from the date of inclusion to the date of death., Up to 36 months from FPI|Time to treatment failure(TTF), TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause., Up to 18 months from randomization date|Duration of response(DOR), DOR is the time between the initial response to therapy and subsequent disease progression or relapse., Up to 18 months from randomization date|Disease control rate(DCR), DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization., Up to 18 months from randomization date|Quality of life(QoL), Evaluate changes compared to baseline using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), after randomization(C1D1), D1 of every 3rd cycle(each cycle consists of 28 days) up to 18 months|PK, Pharmacokinetics is defined as the study of the time course of drug absorption, distribution, metabolism, and excretion., The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of Cycle 1
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.